We identified N-8 as a potent small-molecule drug targeting CTSD, which resulted in excellent therapeutic effects on AML and venetoclax-resistant AML in vitro and in vivo, offering a potential strategy for their treatment. The gene discussed is CTSD; the disease is acute myeloid leukemia.